Marcia Belvin - 13 Jun 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Issuer symbol
CTMX
Transactions as of
13 Jun 2025
Net transactions value
-$37,334
Form type
4
Filing time
17 Jun 2025, 16:10:00 UTC
Previous filing
20 Mar 2025
Next filing
30 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BELVIN MARCIA SVP, Chief Scientific Officer C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO /s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin 17 Jun 2025 0001970752

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +37,500 +15% $0.000000 286,136 13 Jun 2025 Direct F1, F2
transaction CTMX Common Stock Sale $37,334 -13,884 -4.9% $2.69 272,252 16 Jun 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units Options Exercise $0 -37,500 -100% $0.000000 0 13 Jun 2025 Common Stock 37,500 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
F2 Includes 158,958 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
F4 Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.